Francisco Javier Bosques-Padilla

Francisco Javier Bosques-Padilla

Auto-generated profile, based on publicly available information

Francisco Javier Bosques-Padilla

Hospital Universitario, Departamento de Gastroenterología, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2019 in Nature
Verified
Journal Article
Closed access
PDF file
YDYi Duan
Yi Duan
CLCristina Llorente
Cristina Llorente
SLSonja Lang
Sonja Lang
KBKatharina Brandl
Katharina Brandl
HCHuikuan Chu
Huikuan Chu
BSBernd Schnabl
Bernd Schnabl

22 June 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
SLSonja Lang
Sonja Lang
YDYi Duan
Yi Duan
JLJinyuan Liu
Jinyuan Liu
MTManolito G. Torralba
Manolito G. Torralba
CKClaire Kuelbs
Claire Kuelbs
BSBernd Schnabl
Bernd Schnabl

1 March 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
HCHuikuan Chu
Huikuan Chu
YDYi Duan
Yi Duan
SLSonja Lang
Sonja Lang
LJLu Jiang
Lu Jiang
YWYanhan Wang
Yanhan Wang
BSBernd Schnabl
Bernd Schnabl

1 February 2020 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
PKPaulo Kotze
Paulo Kotze
FUFox E. Underwood
Fox E. Underwood
ADAderson Omar Mourão Cintra Damião
Aderson Omar Mourão Cintra Damião
JFJose Geraldo P. Ferraz
Jose Geraldo P. Ferraz
RSRogerio Saad-Hossne
Rogerio Saad-Hossne
GKGilaad Kaplan
Gilaad Kaplan
The incidence of inflammatory bowel diseases (IBD) is increasing in Latin America. We performed a systematic review to identify clinical and epidemiologic features of IBD in Latin America (including Mexico, Central America, and South America) and the Caribbean. We searched MEDLINE, EMBASE, and SciELO databases for clinical or epidemiologic studies of Crohn's disease (CD) or ulcerative colitis (UC) from Latin American and Caribbean countries and territories that reported incidence, prevalence, ratio of UC:CD, IBD phenotype, and treatment, through September 12, 2018. Data were extracted from 61 articles for analysis. The incidence and prevalence of IBD have been steadily increasing in Latin America and the Caribbean. The incidence of CD in Brazil increased from 0.08 per 100,000 person-years in 1988 to 0.68 per 100,000 person-years in 1991-1995 to 5.5 per 100,000 person-years in 2015. The highest reported prevalence of IBD was in Argentina, in 2007, at 15 and 82 per 100,000 person-years for CD and UC, respectively. The ratio of UC:CD exceeded 1 in all regions throughout Latin America and the Caribbean with the exception of Brazil. Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014). Surgery for IBD decreased with time. In Chile, surgeries were performed on 57.0% of patients with CD and 18.0% of patients with UC during the period of 1990-2002; these values decreased to 38.0% and 5.0%, respectively, during the period of 2012-2015. In Peru, 6.9% of patients with UC received colectomies in the period of 2001-2003 and 6.2% in 2004-2014. In a systematic review, we found the incidence of IBD to be increasing throughout Latin America and the Caribbean. Population-based epidemiology studies are needed to evaluate the increase in IBD in these regions, which differ from other global regions in climate, culture, demographics, diet, healthcare delivery and infrastructure, and socioeconomic status.

1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
Elvira Garza-GonzálezElvira Garza-González
Elvira Garza-González
Guillermo Perez PerezGuillermo Perez Perez
Guillermo Perez Perez
HMHéctor Jesús Maldonado-Garza
Héctor Jesús Maldonado-Garza
FBFrancisco Javier Bosques-Padilla
Francisco Javier Bosques-Padilla
Helicobacter pylori (H. pylori) affects nearly half of the world's population and, thus, is one of the most frequent and persistent bacterial infections worldwide. H. pylori is associated with peptic ulcer disease, gastric ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Various diagnostic methods exist to detect infection, and the choice of one method or another depends on several factors, such as accessibility, advantages and disadvantages of each method, cost, and the age of patients. Once H. pylori infection is diagnosed, the clinician decides whether treatment is necessity, according to the patient's clinical condition. Typically, eradication of H. pylori is recommended for treatment and prevention of the infection. Cure rates with the standard triple therapy are acceptable, and effective quadruple therapies, sequential therapies, and concomitant therapies have been introduced as key alternatives to treat H. pylori infection. In this work, we review the main diagnostic methods used to identify H. pylori infection and to confirm eradication of infection. In addition, key factors related to treatment are reviewed.

11 November 2004 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EGElvira Garza‐González
Elvira Garza‐González
FBFrancisco Javier Bosques‐Padilla
Francisco Javier Bosques‐Padilla
Emad El-OmarEmad El-Omar
Emad El-Omar
GHGeorgina Louise Hold
Georgina Louise Hold
RTRolando Tijerina‐Menchaca
Rolando Tijerina‐Menchaca
Guillermo Perez PerezGuillermo Perez Perez
Guillermo Perez Perez
Several cytokine gene polymorphisms have been associated with increased risk of distal gastric cancer (GC) and its precursor histological markers in Caucasian, Asian and Portuguese populations although little is known about their role in other ethnic groups. Our study investigates the role of the IL‐1B‐31, IL‐1RN and TNF‐A‐308 gene polymorphisms as risk factors for the development of GC in a Mexican population. We studied 278 patients who were enrolled at the Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León. The subjects were divided into 2 groups. Sixty‐three patients with histologically confirmed distal GC (mean age = 58.8 years, range = 22–84, F:M = 0.56), and 215 patients with no evidence of distal or proximal GC (mean age = 56.1 years, range = 18–92, F:M = 1.17). The IL‐1B‐31 and the TNF‐A‐308 polymorphisms were determined by PCR‐RFLP and pyrosequencing, respectively, in all cases and controls. The VNTR polymorphism in intron 2 of the 1L‐1RN gene was typed by PCR in 25 cases and 201 controls. The H. pylori status was determined by histology, rapid urease test, culture and serology for non‐cancer controls and by histology for the GC cases. The carriage of the proinflammatory IL‐1B‐31*C allele was associated with increased risk of distal GC (odds ratio [OR] = 7.63, 95% confidence interval [CI] = 1.73‐46.94, p = 0.003). When cases and controls were matched by age and gender, the OR value was higher (OR = 8.05, 95% CI = 1.8–50.22, p = 0.001). When only H. pylori GC cases and controls were compared, the OR value was 7.8 (95% CI = 1.05–161.8, p = 0.04). No association was found between any of the other polymorphisms studied and distal GC. In this Mexican population, the IL‐1B proinflammatory genotype increases the risk of distal GC. These findings are similar to previous reports in Caucasian populations and underscore the importance of cytokine gene polymorphisms in the development of distal GC.